1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 20 APRIL 2015

Cancer Drug News 20 APRIL 2015

  • April 2015
  • -
  • Espicom Business Intelligence
  • -
  • 20 pages

Industry Trend Analysis - Argos/Lummy Deal Indicative Of Shift Towards Innovation Within Sino-foreign Partnerships
Industry Trend Analysis - Positive Ibrance Data Set Pfizer Further Ahead Although Competition Will Arrive Soon
Industry Brief - Genmab Earns Fifth Milestone In Daratumumab Collaboration with Janssen
Industry Trend Analysis - Expansion Of Copanlisib Programme Highlights Changes Within Bayer And The NHL Market
Industry Brief - FDA Accepts NDA Filing For Bendamustine Rapid Infusion
Industry Brief - Panther Licenses TDZD-8 From University Of Rochester For Leukaemia
Industry Brief - Merck KGaA/Pfizer Initiate Avelumab Phase III Study In Stage IIIb/IV NSCLC
Industry Brief - FDA Grants ODD To AstraZeneca's Tremelimumab For Malignant Mesothelioma
Industry Brief - Opdivo Phase III LC Trial Stopped Early Following Favourable OS Results
Industry Trend Analysis - Keytruda's Impending Approval Will Cause BMS' NSCLC Advantage To Slip
Industry Brief - Health Canada Approves New Indication For Xtandi In MCRPCA
Industry Brief - Active Biotech/Ipsen Discontinue Tasquinimod Development In PCA
Industry Brief - MHRA Approves New Indication For Somatuline Autogel
Industry Brief - 4SC/Menarini Sign Resminostat Licensing Deal In Asia-Pacific
Industry Brief - Transgene/FDA Reach SPA Agreement On Pexa-Vec Phase III Trial
Industry Brief - FDA Grants ODD To Oncolytics' Reolysin For Malignant Glioma
Industry Brief - RXi's Samcyprone Gains FDA ODD For Late-Stage Malignant Melanoma
Industry Brief - Provectus Begins PV-10 Phase III Comparative Trial For Melanoma
Industry Brief - AstraZeneca's Selumetinib Gains FDA ODD For Uveal Melanoma
Industry Brief - TetraLogic/Merck Collaborate On Keytruda/Birinapant Combination Phase I Trial In Solid Tumours
Industry Brief - Ventana/Astellas To Co-Develop Tissue Diagnostics For Targeted Cancer Therapies
Industry Brief - Immunocore/MedImmune Enter Second Collaboration
Industry Brief - US Patent Allowance Granted Covering PV-10 For Cancer
Industry Brief - Sanofi To Apply Innate's Site-Specific Conjugation Technology To Develop ADCs
Industry Trend Analysis - Roche's Pipeline Will Benefit From Genomic Diagnostic Acquisition
Industry Brief - TVM Life Science Ventures VII Invests In Esperas Pharma
Industry Trend Analysis - J&J Oncology Segment Gaining Momentum
Industry Brief - Innocrin Raises Funds To Accelerate VT-464 Development In CRPCA

Table Of Contents

Cancer Drug News 20 APRIL 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts Summary Companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...


Download Unlimited Documents from Trusted Public Sources

Hospital Statistics in the US

  • March 2017
    16 pages
  • Hospital  

    Breast Cancer  

  • United States  

View report >

OTC Markets in the US

  • March 2017
    10 pages
  • Pancreatic Canc...  

    Vitamin  

  • United States  

View report >

Cancer and Colorectal Cancer Statistics in the UK - Forecast

  • March 2017
    91 pages
  • Cancer  

    Colorectal Canc...  

    Health Care Pro...  

  • United Kingdom  

View report >

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.